Mean Rectal Radiation Dose in Clinically Localized Prostate Cancer Treated with Moderate Hypofractionated Radiotherapy

Imad  Ullah; Rab Nawaz  Maken; Jasim  Muzaffar; Faraz  Saif; Iqra  Iftikhar

doi:10.36283/ziun-pjmd14-4/091

Authors

Imad Ullah Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.
Rab Nawaz Maken Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.
Jasim Muzaffar Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.
Faraz Saif Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.
Iqra Iftikhar Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.

DOI:

https://doi.org/10.36283/ziun-pjmd14-4/091

Keywords:

Radiotherapy, Rectum, Radiation Dosage, Dose-Response Relationship, Cross-Sectional Studies

Abstract

Background: Globally, prostate cancer is among the most common cancers affecting men. While external beam radiation therapy (EBRT) is essential for its management, radiation exposure to adjacent organs, including the rectum, may lead to gastrointestinal toxicity. This study aimed to ascertain the average radiation dose to the rectum in patients with moderately hypo-fractionated radiation therapy for clinically localized prostate cancer.

Methods: Between June and August of 2025, a retrospective cross-sectional study was carried out at the INMOL Hospital's Department of Radiotherapy in Lahore. There were 55 male patients with histologically confirmed localized prostate adenocarcinoma (T1c–T3a N0 M0) who were between the ages of 40 and 80. All were given 60 Gray (Gy) in 20 fractions (3 Gy per fraction) via Intensity-Modulated Radiation Therapy (IMRT). The dose-volume histograms (DVHs) were used to extract the rectal dosimetric parameters. Chi-square and t-tests were used (p-value<0.05) via SPSS v26.0.

Results: The patients were primarily elderly, with a mean age of 68.4 ± 8.7 years. Within the recommended tolerance limits, the average rectal dose was 29.2 ± 3.6 Gy, indicating consistent treatment delivery. The correlation between age and mean rectal dose was weak and statistically non-significant (r = 0.18, p = 0.12), but there was a significant relationship between tumor grade and clinical stage (χ² = 9.12, p = 0.037, Cramer's V = 0.29).

Conclusion: Consistent rectal dose limitation was accomplished by moderately hypo-fractionated IMRT without reducing disease coverage.

Author Biographies

Imad Ullah, Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.

Department of Oncology,
Rab Nawaz Maken, Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.

Department of Oncology,
Jasim Muzaffar, Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.

Department of Oncology,
Faraz Saif, Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.

Department of Oncology,
Iqra Iftikhar, Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.

Department of Oncology,

References

1. Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. Eur Urol. 2023 Aug;84(2):191-206. doi: 10.1016/j.eururo.2023.04.021.

2. Llewellyn A, Phung TH, O Soares M, Shepherd L, Glynn D, Harden M, et al. MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2024 Oct;28(61):1-310. doi: 10.3310/PLFG4210.

3. Lo Greco MC, Marletta G, Marano G, Fazio A, Buffettino E, Iudica A, et al. Hypofractionated Radiotherapy in Localized, Low-Intermediate-Risk Prostate Cancer: Current and Future Prospectives. Medicina (Kaunas). 2023 Jun 14;59(6):1144. doi: 10.3390/medicina59061144.

4. Chatterjee R, Chan J, Mayles H, Cicconi S, Syndikus I. Long-term Results of Hypofractionated Radiotherapy With Intra-prostatic Boosts in Men With Intermediate- and High-risk Prostate Cancer: A Phase II Trial. Clin Oncol (R Coll Radiol). 2024 Dec;36(12):e473-e482. doi: 10.1016/j.clon.2024.08.011.

5. Mariados NF, Orio PF 3rd, Schiffman Z, Van TJ, Engelman A, Nurani R, et al. Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial. JAMA Oncol. 2023 Apr 1;9(4):511-518. doi: 10.1001/jamaoncol.2022.7592.

6. Takagi M, Hasegawa Y, Tateoka K, Takada Y, Hareyama M. Dosimetric Comparison Study of Proton Therapy Using Line Scanning versus Passive Scattering and Volumetric Modulated Arc Therapy for Localized Prostate Cancer. Cancers (Basel). 2024 Jan 17;16(2):403. doi: 10.3390/cancers16020403.

7. Zhang L, Liu X, Xia R, Chen F, Wang X, Bao J, et al. Comparison of the clinicopathologic features of prostate cancer in US and Chinese populations. Pathol Res Pract. 2022 Jun;234:153933. doi: 10.1016/j.prp.2022.153933.

8. Raza SA. Emerging Trends in Global Cancer Epidemiology. Cancers (Basel). 2025 Apr 28;17(9):1483. doi: 10.3390/cancers17091483.

9. Beatrici E, Filipas DK, Stone BV, Labban M, Qian Z, Lipsitz SR, et al. Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade. Urol Oncol. 2023 Dec;41(12):483.e11-483.e19. doi: 10.1016/j.urolonc.2023.09.012.

10. Bryant AK, Nelson TJ, McKay RR, Kader AK, Parsons JK, Einck JP, et al. Impact of age on treatment response in men with prostate cancer treated with radiotherapy. BJUI Compass. 2021 Dec 27;3(3):243-250. doi: 10.1002/bco2.132.

11. Bhardwaj R, Agrawal U, Vashist P, Manna S. Determination of sample size for various study designs in medical research: A practical primer. J Family Med Prim Care. 2024 Jul;13(7):2555-2561. doi: 10.4103/jfmpc.jfmpc_1675_23.

12. Murgić J, Gregov M, Mrčela I, Budanec M, Krengli M, Fröbe A, et al. MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM. Acta Clin Croat. 2022 Oct;61(Suppl 3):65-70. doi: 10.20471/acc.2022.61.s3.9.

13. Huang S, Wu J, Lin X, Wang G, Song T, Chen L, et al. Auto-Segmentation and Auto-Planning in Automated Radiotherapy for Prostate Cancer. Bioengineering (Basel). 2025 Jun 6;12(6):620. doi: 10.3390/bioengineering12060620. PMID: 40564436; PMCID: PMC12189893.

14. Jones EL DClinSci, Oppong P, Sisodia C, Napoleone-Filho C, Harris V, Golby C, et al. Automated contouring and radiotherapy treatment planning of spine metastases using atlas-based auto-segmentation and knowledge-based planning approaches. Br J Radiol. 2025 Jul 1;98(1171):1143-1154. doi: 10.1093/bjr/tqaf041.

15. Ingrosso G, Ponti E, Francolini G, Caini S, Fondelli S, Santini R, et al. Image-guided moderately hypofractionated radiotherapy for localized prostate cancer: a multicentric retrospective study (IPOPROMISE). Radiol Med. 2024 Apr;129(4):643-652. doi: 10.1007/s11547-024-01782-2.

16. Yan M, Gouveia AG, Cury FL, Moideen N, Bratti VF, Patrocinio H, et al. Practical considerations for prostate hypofractionation in the developing world. Nat Rev Urol. 2021 Nov;18(11):669-685. doi: 10.1038/s41585-021-00498-6.

17. Shan G, Hu W, Chen L, Price RA, Ma CC. Dosimetric evaluation of image-guided radiation therapy for prostate cancer. Med Dosim. 2021 Summer;46(2):117-126. doi: 10.1016/j.meddos.2020.09.007.

18. Baccaglini W, de Carvalho IT, Glina FPA, Pazeto CL, Marantes A, Nascimento M, et al. Radiotherapy-related toxicity for localized prostate cancer: meta-analysis comparing conventional or moderately hypofractionated vs. ultrahypofractionated protocols. Clin Transl Oncol. 2022 Jul;24(7):1425-1439. doi: 10.1007/s12094-022-02790-2.

19. Franzese C, Badalamenti M, Baldaccini D, D'Agostino G, Comito T, Franceschini D, et al. Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. Strahlenther Onkol. 2021 Feb;197(2):133-140. doi: 10.1007/s00066-020-01691-z.

20. Paskalice K, Joseph J, Krishna Kumarapillai Mohanan Nair J, Kumar A, James FV. Acute toxicity of moderate hypofractionated radiotherapy in localized carcinoma prostate: An observational study. J Cancer Res Ther. 2025 Apr 1;21(3):602-605. doi: 10.4103/jcrt.jcrt_846_24.

21. Schmidt DR, Bhagwat M, Glazer DI, Chen MH, Moteabbed M, McMahon E, et al. MRI-Based Radiotherapy Planning to Reduce Rectal Dose in Excess of Tolerance. Prostate Cancer. 2022 Feb 3;2022:7930744. doi: 10.1155/2022/7930744.

22. Ferreira MR, Thomas K, Truelove L, Khan A, Parker C, Dearnaley DP, et al. Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer. Clin Oncol (R Coll Radiol). 2019 Jun;31(6):374-384. doi: 10.1016/j.clon.2019.02.012.

23. Kougioumtzopoulou A, Syrigos N, Zygogianni A, Georgakopoulos I, Platoni K, Patatoukas G, et al. Comprehensive 3DCRT Hypofractionated Radiotherapy Schedule for Localized Prostate Adenocarcinoma in the Era of IMRT: Dosimetric and Endoscopic Analysis. Cancers (Basel). 2024 Mar 18;16(6):1192. doi: 10.3390/cancers16061192.

24. Kikuchi K, Segawa T, Ieko Y, Oikawa H, Nakamura R, Ariga H. Toxicity and patient-reported outcomes after moderately hypofractionated radiotherapy (60 Gy in 20 fractions) for prostate cancer: prospective observational study. J Radiat Res. 2025 Sep 24:rraf059. doi: 10.1093/jrr/rraf059.

25. Ozyigit G, Hurmuz P, Bayatfard P, Tilki B, Yedekci Y, Yilmaz MT. Predicting acute and late toxicity in prostate cancer stereotactic ablative radiotherapy: the role of dosimetric parameters and prostate volume. Strahlenther Onkol. 2025 Aug;201(8):788-798. doi: 10.1007/s00066-024-02343-2.